TipRanks (Thu, 12-Dec 6:16 AM ET)
Piper Sandler Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
TipRanks (Wed, 11-Dec 6:45 AM ET)
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
Business Wire (Thu, 5-Dec 8:30 AM ET)
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Globe Newswire (Tue, 3-Dec 8:00 AM ET)
Globe Newswire (Tue, 26-Nov 8:00 AM ET)
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Globe Newswire (Wed, 6-Nov 5:00 PM ET)
Globe Newswire (Wed, 6-Nov 7:30 AM ET)
Globe Newswire (Fri, 1-Nov 8:00 AM ET)
Globe Newswire (Thu, 26-Sep 8:00 AM ET)
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.
As of December 16, 2024, PRAX stock price climbed to $72.83 with 37,382 million shares trading.
PRAX has a beta of 1.35, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.03 to the broad based SPY ETF.
PRAX has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Praxis Precision Medicines reported $302,000 in Revenue and -$2.75 earnings per share. This beat revenue expectation by $2,000 and missed earnings estimates by -$.76.
In the last 3 years, PRAX traded as high as $312.75 and as low as $11.85.
The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
PRAX has outperformed the market in the last year with a return of +334.5%, while the SPY ETF gained +30.5%. In the last 3 month period, PRAX beat the market returning +21.6%, while SPY returned +8.3%. However, in the most recent 2 weeks PRAX has underperformed the stock market by returning -9.2%, while SPY returned +0.7%.
PRAX support price is $67.08 and resistance is $73.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.